• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Metabolism
    • Anti-infectives
    • Cancer
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Euronext Growth
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
July 27, 2015

ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

Read More
July 25, 2015

Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

Read More
June 25, 2015

Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™

Read More
May 29, 2015

ANNUAL GENERAL MEETING: 2015

Read More
May 07, 2015

Notice of Annual General Meeting: 29 May 2015

Read More
April 30, 2015

Preliminary Results Announcement for the year ended 31 December 2014

Read More
April 30, 2015

Dr Stéphane Méry Appointed as Non-Executive Director

Read More
February 11, 2015

Cancer Update: IPP-204106

Read More
January 27, 2015

Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status

Read More
January 22, 2015

Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion

Read More
October 21, 2014

ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France

Read More
October 21, 2014

AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress

Read More
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2020 | All rights reserved

Cookies

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy